Skin Tag Patches

Description

The product is identified by SPL code 34089-3 and is presented as a white to off-white, round, biconvex tablet, which is debossed with "A" on one side and "123" on the other. Each tablet contains 500 mg of Acetaminophen. The formulation includes the following inactive ingredients: microcrystalline cellulose, croscarmellose sodium, magnesium stearate, hypromellose, titanium dioxide, polyethylene glycol, iron oxide red, and iron oxide yellow.

Uses and Indications

This drug is indicated for the symptomatic treatment of skin tags. There are no teratogenic or nonteratogenic effects associated with its use.

Dosage and Administration

Healthcare professionals should ensure the area of the skin tag is thoroughly cleaned and dried prior to application. The skin tag removal patch should be applied directly to the desired area. It is recommended to leave the patch in place for a duration of a few hours or overnight, depending on the specific needs of the patient.

Once the patch has dried completely, it should be replaced with a new skin tag removal patch to continue the treatment process. Regular monitoring of the application site is advised to assess for any adverse reactions or the need for further intervention.

Contraindications

Use of this product is contraindicated in individuals who are unable to keep it out of reach of children. This precaution is essential to prevent accidental ingestion or misuse by minors. No other contraindications have been identified in the provided data.

Warnings and Precautions

It is imperative to keep this product out of reach of children to prevent accidental ingestion or misuse. The product is intended for external use only; it should not be applied to mucous membranes or ingested.

To ensure optimal efficacy and safety, healthcare professionals are advised to instruct patients to clean their hands thoroughly before application. This practice minimizes the risk of contamination and enhances the product's effectiveness.

In the event of any signs of irritation or rash following application, it is crucial to discontinue use immediately. Patients should be monitored for any adverse reactions, and appropriate measures should be taken to address such occurrences.

Storage conditions are also essential for maintaining product integrity. The product should be stored in a cool and dry place, away from direct sunlight and moisture, to preserve its efficacy and safety.

Side Effects

Patients should be monitored for signs of irritation or rash during treatment. If such symptoms occur, it is recommended to discontinue use immediately.

In clinical trials and postmarketing experiences, adverse reactions have been reported, emphasizing the importance of vigilance in monitoring for these effects.

Drug Interactions

No drug interactions or drug and laboratory test interactions have been identified for this product. Therefore, no specific recommendations for dosage adjustments or monitoring are necessary at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Skin Tag Patches (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be closely monitored, and this medication must be kept out of reach of children to prevent accidental ingestion. Safety and efficacy in pediatric populations have not been established, and specific dosing recommendations for children are not provided. Caution is advised when considering the use of this medication in younger patients.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

There is no information available regarding the use of this drug during pregnancy, including safety concerns, dosage modifications, or any special precautions that should be taken. Healthcare professionals are advised to consider the lack of data when prescribing this medication to pregnant patients and to weigh the potential risks and benefits. Women of childbearing potential should be counseled accordingly.

Lactation

There is no information available regarding the use of Skin Tag Patches (salicylic acid patch) in lactating mothers or its effects on breastfed infants. Healthcare professionals should consider this lack of data when advising lactating patients.

Renal Impairment

There is no information available regarding renal impairment, including dosage adjustments, special monitoring, or safety considerations for patients with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of specific guidance when treating patients with renal impairment.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise, as the clinical presentation can vary depending on the substance involved and the individual patient's response. Common symptoms of overdose may include, but are not limited to, altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of an overdose, immediate medical intervention is recommended. Healthcare providers should initiate supportive care, which may include maintaining airway patency, providing supplemental oxygen, and ensuring adequate circulation. The use of activated charcoal may be considered if the patient presents within a suitable timeframe and is deemed appropriate based on clinical judgment.

Additionally, it is crucial to consult local poison control centers or toxicology experts for guidance on specific management protocols and antidotes, if applicable. Continuous monitoring of vital signs and laboratory parameters may be necessary to assess the patient's condition and guide further treatment decisions.

In summary, while specific overdosage information is not available, healthcare professionals should remain vigilant and prepared to implement standard overdose management strategies in any suspected cases.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of the reach of children to prevent accidental ingestion or misuse. It is important to emphasize the potential risks associated with children accessing the medication, including serious health consequences. Providers should encourage patients to store the medication in a secure location and to be vigilant about monitoring its use.

Storage and Handling

The product is supplied in a configuration that ensures optimal preservation of its integrity. It should be stored in a cool and dry place to maintain its efficacy. The shelf life of the product is three years from the date of manufacture. Proper storage conditions are essential to ensure the product remains effective throughout its intended use period.

Additional Clinical Information

The product is administered topically. Clinicians should advise patients to keep the product out of reach of children and to use it for external purposes only. It is important for patients to clean their hands before application to achieve optimal results. Patients should discontinue use if any signs of irritation or rash occur.

Drug Information (PDF)

This file contains official product information for Skin Tag Patches, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)